Skye Bioscience is no longer an obesity company in any operating sense. After the CBeyond monotherapy miss and a commercial profile that required a bulky weekly injection, management halted nimacimab development and cut the organization to a two-person residual staff. The residual public vehicle is now a going-concern shell trying to close a United Kingdom scheme of arrangement that folds Redx Pharma into a Nasdaq-listed fibrosis company to be renamed Fibrx Therapeutics. Pre-deal holders keep a mid-single-digit stake in the combined entity plus a one-year contingent value right on any nimacimab sale.
The mid-year balance sheet makes that transaction the only realistic path. Cash and short-term investments stood near $10 million. A legal contingency above $5 million sits against that cash, and stockholders equity flipped to a deficit after the program wind-down, asset write-offs, and the Cunning reserve increase. Research spending collapsed once the trial stopped, which narrowed the quarterly loss but also confirmed that the obesity franchise no longer supports a standalone cost base. The market is pricing a small option on deal close, not a going obesity platform.
Net loss for the quarter narrowed toward $11 million as the trial closed. Combined-company financing commitments near $125 million are meant to carry Fibrx through a Phase Two readout of RXC008, a gut-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease, with data not due until late in the decade. The open question is whether Skye stockholders approve a transaction that leaves them with a sliver of a United Kingdom-led fibrosis company, or whether a failed close leaves a two-employee issuer with a going-concern paragraph and a looming Cunning retrial.